- Home
- NCPL vs REVB Comparison
NCPL vs REVB Comparison
Compare NCPL & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- REVB
- Stock Information
- Founded
- NCPL 1984
- REVB 2020
- Country
- NCPL United States
- REVB United States
- Employees
- NCPL N/A
- REVB N/A
- Industry
- NCPL Investment Managers
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- REVB Health Care
- Exchange
- NCPL Nasdaq
- REVB Nasdaq
- Market Cap
- NCPL 4.3M
- REVB 3.7M
- IPO Year
- NCPL N/A
- REVB N/A
- Fundamental
- Price
- NCPL $7.00
- REVB $2.58
- Analyst Decision
- NCPL
- REVB
- Analyst Count
- NCPL 0
- REVB 0
- Target Price
- NCPL N/A
- REVB N/A
- AVG Volume (30 Days)
- NCPL 907.7K
- REVB 458.9K
- Earning Date
- NCPL 07-28-2025
- REVB 08-08-2025
- Dividend Yield
- NCPL N/A
- REVB N/A
- EPS Growth
- NCPL N/A
- REVB N/A
- EPS
- NCPL N/A
- REVB N/A
- Revenue
- NCPL $812,612.00
- REVB N/A
- Revenue This Year
- NCPL N/A
- REVB N/A
- Revenue Next Year
- NCPL $101.16
- REVB N/A
- P/E Ratio
- NCPL N/A
- REVB N/A
- Revenue Growth
- NCPL N/A
- REVB N/A
- 52 Week Low
- NCPL $1.41
- REVB $0.70
- 52 Week High
- NCPL $11.90
- REVB $56.00
- Technical
- Relative Strength Index (RSI)
- NCPL 66.76
- REVB 35.98
- Support Level
- NCPL $5.25
- REVB $2.11
- Resistance Level
- NCPL $8.75
- REVB $2.49
- Average True Range (ATR)
- NCPL 1.18
- REVB 0.23
- MACD
- NCPL 0.31
- REVB 0.23
- Stochastic Oscillator
- NCPL 71.60
- REVB 56.80
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).